Pralatrexate
Brand and Other Names:
Folotyn
Mechanism of Action:
Pralatrexate is a folate analog metabolic inhibitor that competitively inhibits dihydrofolate reductase.
Indications:
FOLOTYN is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
Route:
Intravenous
Dose:
The recommended dose of FOLOTYN is 30 mg/m2 administered as an intravenous push over 3-5 minutes via the side port of a free-flowing 0.9% Sodium Chloride Injection for once weekly for 6 weeks in 7 week cycles. For patients with severe renal impairment (eGFR 15 to < 30 mL/min/1.73 m2), the recommended dose of FOLOTYN is 15 mg/m2. Prior to initiating FOLOTYN, supplement patients with vitamin B12 1 mg intramuscularly every 8- 10 weeks and folic acid 1.0-1.25 mg orally on a daily basis.
Adverse Reactions:
Most common adverse reactions (>35%) are mucositis, thrombocytopenia, nausea, and fatigue. Most
common serious adverse reactions are pyrexia, mucositis, sepsis, febrile neutropenia, dehydration, dyspnea, and thrombocytopenia.
Contraindication:
None
Warnings and Precautions:
FOLOTYN can cause bone marrow suppression, manifested by thrombocytopenia, neutropenia, and/or anemia.
See package insert for full prescribing information.